GlaukosGKOS
Recorded

Glaukos Stifel 2026 Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration30 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Tom StephanAnalyst

Okay. Good morning, everyone. Tom Stephan with Stifel. Welcome to the 2026 Stifel Healthcare Conference. Excited to have Glaukos here with us today, coming off a very strong Q3 print. Joe, Alex, Chris, thanks so much for joining.

Joe GilliamPresident and COO

Thanks for having us. I will dive right in.

Tom StephanAnalyst

I think we have around 30 minutes. I will start with EPIOXA. Joe, I will kick things off with you. Maybe talk about how payer progress has tracked to date relative to, call it, internal expectations, maybe specifically touching on approval rates, time to approval, kind of how that is tracking.

Joe GilliamPresident and COO

Yeah. Thanks, Tom. Again, thanks for having us as a part of the conference this year. As it relates to EPIOXA and our payer progress, I would say generally speaking, it has gone much better than what we had expected internally. I give a lot of credit to our teams, our payer relations team, our broader market access team, and the approach, our medical affairs team, and the folks who have educated these payers from a clinical perspective. We obviously had a variety of scenarios as we evaluated how this would go at the beginning, but from our standpoint, it has really been a successful launch thus far from a payer perspective and a site of care perspective, as we talked about on the most recent earnings call.

Joe GilliamPresident and COO

That doesn't mean that there's not all the normal process-related headwinds that come from the payer community, especially when you have a commercially insured patient population. We do experience that. Most of that is normal and certainly within the realm of what we expected. At this point, when you look at the statistics we talked about on the last call, we're really pleased with the amount of coverage we have, not just in the commercial insured patient population, but also within the Medicaid patient population. So we've really done a great job of establishing access pathways for the patients that are seeking therapy on EPIOXA.

Tom StephanAnalyst

Got it. That's helpful. I think I'll call it the near-term payer progress. It does sound like it's going quite well. There's receptivity from the payers. How do we think about intermediate-term payer risk? Is there anything we have to, call it, consider or be mindful of, particularly if EPIOXA grows rapidly from a volume standpoint and the reimbursement dollars grow as well alongside that? Maybe talk about kind of that intermediate-term payer dynamics.

Joe GilliamPresident and COO

Yeah. Well, I think the short and the intermediate term are somewhat similar as you grow in volumes. I think, again, as you launch a new drug, in our case, EPIOXA and corneal cross-linking, the most important thing is to remember it already is the standard of care. Corneal cross-linking is the standard of care. We established that with Photrexa. It's the best available alternative for patients afflicted with keratoconus today, and really does slow or halt the progression of that sight-threatening disease. From that standpoint, you've always got that as your backdrop. Now, it doesn't mean that insurance carriers won't play various tactics that help to try to slow things down. We see that already today. There's a variety of things around the timeliness in which they pay, system issues around the way they have the J-code loaded or the way they do the payments.

Joe GilliamPresident and COO

There's a whole variety of things that are all process-oriented that can come out and can slow you in any given week, month, quarter, et cetera. That's why your teams have to stay vigilant and on top of these insurance carriers, as well as the customers themselves. We expect that. I think from an overall, call it, policy perspective, a lot of the policies around corneal cross-linking have already been established. They can always be looking at those things and trying to make tweaks there, but it's a pretty established category from a disease perspective. If anything, we've seen over the last several years with Photrexa now having been out there for 10 plus years, we've seen them retire some of those policies as the rate of prior authorization approvals have been quite high.

Tom StephanAnalyst

Got it. Very helpful. Sticking kind of near term, hopefully I have these numbers right, $11 million in 2Q. EPIOXA sales jumped very nicely to $53 million in 3Q. Consensus I am seeing is at around only $75 million in the fourth quarter. I think by my math, that is an increase of maybe 300% to 400% sequentially. Any factors we should be cognizant of with the fourth quarter that might moderate the growth curve and would result in that subdued sequential growth?

Joe GilliamPresident and COO

Well, first, I probably will quibble with the terminology only $75 million in the third quarter of launch for the drug. I think it is probably a little bit early to be analyzing growth curves. I think we are still very much in the early days of this launch, and there are a lot of factors at play, including some of the stuff we already mentioned. I think we just continue to put one foot in front of the other. As we have said publicly, we have a very strong top of the funnel, right? Our site of care network is strong. The number of patients coming into our hub seeking access to therapy is strong. That should not surprise you necessarily given the legacy of Photrexa, and this is not a new disease category.

Joe GilliamPresident and COO

But we have got to continue to put one foot in front of the other and make sure that we are getting these patients approved and scheduled and treated, and ultimately the product shipped. I think we will continue to make progress in the fourth quarter, and how much we will wait until we have got it done to see. I think the only thing we tried to call out around the fourth quarter specifically is we do not exactly know the end of the year dynamics. As strong of a trend line as we are on, obviously coming out of the third quarter, you do not know when you get into kind of that December timeframe how much of the procedures we will be able to get scheduled before your benefits expire versus the types of things where insurance companies will delay and try to push you into the new year.

Joe GilliamPresident and COO

Given this is our first end of the year with this drug, we want to make sure and be thoughtful about that dynamic.

Tom StephanAnalyst

Makes sense. Sticking with EpiCornea, but maybe thinking more long-term, big picture. The U.S. corneal cross-linking market at peak, maybe a year or two ago, about 18,000-20,000 eyes, give or take. Talked about the TAM of maybe being 50,000-100,000 eyes that could get treated annually. I guess a two-part question to start. Are those diagnosed eyes, the 50,000-100,000? If so, what's the size of the U.S. market, maybe when factoring in undiagnosed eyes? Maybe if we could parse out that 50,000-100,000.

Joe GilliamPresident and COO

Yeah. First I'll validate what you said. Obviously, the sort of peak from a Photrexa standpoint, we were treating commercially between 18,000 and 20,000 eyes a year. Our objective is to get back to that as fast as we can here with the launch. When we look at broader claims data, and there's a little bit of ambiguity around exactly how physicians have coded this historically between keratoconus, severe progressive keratoconus, and all the things in there. That's the reason why the broader estimate that we cite. But we're fairly confident that there are 50,000-100,000 eyes at any given point in time out there being diagnosed- diagnosed- Yep as severe progressive keratoconus.

Joe GilliamPresident and COO

Now, step two of the sort of launch dynamics is trying to go make sure you're realizing getting as many of those patients access to therapy, because if that's true, obviously all of those should be theoretically good candidates, especially with a therapy like EpiCornea that doesn't require the debridement of the cornea and some of the dynamics around that. More broadly than that, I guess we'll find out. I can't say that we know. I do think ultimately we'll prove that this was perhaps not a rare disease, but it was actually a rarely diagnosed disease. The investments that you've seen from us, we've announced publicly the partnership with Stephen Curry around disease awareness, he himself having obviously had keratoconus, having keratoconus and been treated, is a big part of that.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day